Rome, October 21 (askanews) – A neurological disease with a high clinical, social, and economic impact, capable of significantly compromising the lives of those who suffer from it. Timeliness is crucial in migraine treatment: identifying the patient's needs early and choosing the most appropriate therapy improves outcomes and restores life expectancy. To take stock of the main challenges in managing the disease, in light of scientific advances, the event "Mygraine Time – Shaping Migraine Time" is launching. "Our goal is not just to control the next attack, but as clinicians, we must commit to having a forward-looking vision to change its course.
It means changing the trajectory that would lead us towards greater difficulty; acting promptly to change the course of the disease means truly taking charge of the patient and looking to their future,” said Dr. Daniele Martinelli, Neurologist at the Headache and Neurorehabilitation Center IRCCS Fondazione Mondino in Pavia. “The evolution of the clinician's treatment goals has evolved hand in hand with the availability of available preventive therapies, moving from non-specific therapies, such as antiepileptics and antidepressants, to specific targeted therapies such as anti-CGRP.
And it is precisely thanks to these new therapies, which have demonstrated long-term efficacy and tolerability, that, at the same time, the goals that clinicians set for patients entering the clinic have become increasingly higher,” added Dr. Danilo Antonio Montisano, Neurologist at the Headache Center of the Fondazione IRCCS Istituto Neurologico Carlo Besta in Milan. Through a multidisciplinary approach structured into face-to-face sessions and small-group workshops, the meeting analyzes the overall impact of the pathology. “Chronic migraine represents the most severe form of migraine: it is the one in which a central pain sensitization mechanism coexists with a peripheral mechanism, which is what underlies the actual migraine pain.
And it is precisely for this reason that in chronic migraine it is often necessary to combine specific therapies, such as monoclonal antibodies and gepants, which act peripherally, with repositioning therapies, which act centrally," concluded Dr. Marcello Silvestro, Neurologist and Researcher at the Luigi Vanvitelli University of Campania in Naples. The initiative represents an opportunity to share experiences, take stock of the latest research developments and redesign a more informed, timely and patient-centered treatment perspective.
Askanews